Impact of optimum diabetes care on the safety of fasting in Ramadan in adult patients with type 2 diabetes mellitus on insulin therapy

被引:16
|
作者
Bashier, Alaaeldin M. K. [1 ]
Bin Hussain, Azza Khalifa [1 ]
Alawadi, Fatheya [1 ]
Alsayyah, Fatima [1 ]
Alsaeed, Maryam [1 ]
Rashid, Fauzia [1 ]
Abdelgadir, Elamin [1 ]
Bachet, Fawzi [1 ]
Abuelkheir, Sona [1 ]
Elsayed, Mohamed [1 ]
Hassanein, Mohamed [1 ]
机构
[1] Dubai Hosp, Endocrine Dept, Dubai, U Arab Emirates
关键词
Ramadan; Flash glucose monitoring; Type; 2; diabetes; Hypoglycemia; Hyperglycemia; HbA1c; Basal insulin; Intensive insulin therapy; OPEN-LABEL; GLARGINE; REPAGLINIDE; MULTICENTER; GLIMEPIRIDE; EFFICACY; REGIMEN;
D O I
10.1016/j.diabres.2019.01.037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: We aimed at evaluating the safety of fasting Ramadan for insulin treated type 2 diabetes patients by assessing the biochemical, biometric parameters, flash glucose monitoring (FGM) data as compared to pre-Ramadan and hospital admissions with diabetes or non-diabetes conditions. The risks of fasting between those treated with basal insulin vs intensive insulin during Ramadan was also assessed. Methods: We included insulin treated patients with type 2 diabetes and we excluded those with co-morbidities. Patients were provided with Ramadan-focused education, FGM before and during Ramadan and medical advice for treatment adjustment. We measured biologic and biometric data before and after Ramadan. Results: HbA1c reduced from 7.9 +/- 1.20 pre-Ramadan to 7.7 +/- 1.5% post Ramadan (p = 0.023). Average peak glucose reading was 330.1 +/- 79.8 mg/dl before Ramadan improved significantly to reach 289.3 +/- 77.7 mg/dl (p = 0.013). Average number of hypoglycemic episodes was higher in intensive insulin group between 1200 and 1800 h (p = 0.028). Conclusion: People with type 2 diabetes treated with insulin who fast Ramadan and who are provided with Ramadan focused patient education, individualized treatment adjustment and FGMS were not at increased safety risks as measured by biochemical, biometric and FGM data. (C) 2019 Elsevier B.V. All rights reserved.
引用
收藏
页码:301 / 307
页数:7
相关论文
共 50 条
  • [41] Safe Ramadan Fasting Is Possible for Subjects with Poorly Controlled Type 2 Diabetes Mellitus
    Chee, Ying Jie
    Ng, Shonda
    Kwek, Kevin J.
    Shakoor, Shaikh Abdul Kader Abdul
    DIABETES, 2018, 67
  • [42] Insulin therapy during Ramadan fast for Type 1 diabetes patients
    Kassem, HS
    Zantout, MS
    Azar, ST
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2005, 28 (09) : 802 - 805
  • [43] Impact of Ramadan fasting on young people with diabetes type 1
    Bendeddouche, Ahmed Salih
    Boukli-Hacene, Chakib
    Benasla, Djihane
    Benchikh, Sana
    Senouci, Djawida
    Hamidi, Fatma Wahiba
    Mazari, Wafa
    Bouriche, Khadidja
    Belbachir, H. L.
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 675 - 675
  • [44] Insulin therapy during Ramadan fast for Type 1 diabetes patients
    H. S. Kassem
    M. S. Zantout
    S. T. Azar
    Journal of Endocrinological Investigation, 2005, 28 : 802 - 805
  • [45] Impact of orlistat on fasting hyperglycemia in obese patients with type 2 diabetes mellitus
    Kelley, DE
    OBESITY RESEARCH, 2001, 9 : 188S - 188S
  • [46] Impact of orlistat on fasting hyperglycemia in obese patients with type 2 diabetes mellitus
    Kelley, DE
    DIABETES, 2001, 50 : A439 - A439
  • [47] Technosphere® Insulin: Safety in Type 2 Diabetes Mellitus
    Rossiter, Alicia
    Howard, Campbell P.
    Amin, Nikhil
    Costello, Donald J.
    Boss, Anders H.
    DIABETES, 2010, 59 : A141 - A141
  • [48] Medication and Insulin Therapy Regimens for Diabetes mellitus Part 2: Insulin Therapy for Type 1 and 2 Diabetes mellitus
    Cotney, Sophia
    Lorenz, Corinna
    ERNAHRUNGS UMSCHAU, 2020, 67 (04): : S21 - S25
  • [49] Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh
    Pathan, Md Faruque
    Akter, Nazma
    Selim, Shahjada
    Saifuddin, M.
    Qureshi, Nazmul Kabir
    Kamrul-Hasan, A. B. M.
    Hannan, Mohammad Abdul
    Ahmed, Md Ashraf Uddin
    Mustari, Marufa
    Chakraborty, Ashish Kumar
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGET & THERAPY, 2022, 15 : 4011 - 4021
  • [50] Combined metformin and insulin therapy for patients with type 2 diabetes mellitus
    Ponssen, HH
    Elte, JWF
    Lehert, P
    Schouten, JP
    Bets, D
    CLINICAL THERAPEUTICS, 2000, 22 (06) : 709 - 718